1981
Characterized by chronic swelling, pain, edema, and skin induration.
Characterized by pain swelling, sensation of heaviness, edema, pigmentation, skin deterioration including venous ulcers.
Associated and their quality of life and substantial financial burden.
About half of patients with symptomatic DVT develop some degree of PTS.
Daily use of elastic compression stockings reduces the risk of PTS by about 50%.
Results from venous obstruction, and venous incompetence caused by inflammation of the venous valves in response to acute thrombotic occlusion, or both.
Accelerated removal of thrombus material by thrombolysis can prevent pain dysfunction and PTS.
Catheter directly thrombolysis improves the clinically relevant long-term outcome after iliofemoral obstruction.
Among patients with moderate/severe prothrombotic syndrome and iliac vein obstruction, endovascular therapy leads to less severe post, thrombotic syndrome and better health related quality of life and standard care over six months, but with a higher risk of bleeding. (C-TRACT trial investigator).
DVT by reducing PTS compared with conventional treatment with anti coagulation and an elastic compression stockings alone: absolute reduction in about 14%(CaVent study).
Usually manifests within 1-2 years after DVT (78%).
Incidence after DVT approximately 10-50%.
Approximately 20-50% of patients with proximal DVT develop this syndrome.
Pain swelling,heaviness, edema, skin pigmentation, and in very severe cases the development of an ulcerations characterize this syndrome.
The clinical presentation is diverse and ranges from lower extremity edema to chronic debilitating pain, intractable edema, and venous ulcers, occurring in approximately 5% of patients.
It is suggested obstruction of venous outflow due to impaired thrombus resolution and a thrombus induced inflammatory response with damage of venous valves and vein wall fibrosis causing reflux and venous hypertension.
Post thrombotic syndrome (PTS) markedly impairs quality of life, and parallels the difficulties as those with severe COPD, CHF, or angina pectoris.
Sub therapeutic anticoagulation with warfarin has been associated with a 2-3 fold increased risk of post phlebotic syndrome or a dose response relationship with time in the sub therapeutic range.
Risk factors include iliofemoral DVT, recurrent ipsilateral DVT, persistent symptoms after one month of therapeutic and a coagulation, increased BMI, advanced age, and suboptimal anticoagulation.
The management of postthrombotic syndrome (PTS) centers on compression therapy, lifestyle modifications (exercise, leg elevation, weight management), and wound care for venous ulcers, with endovascular stenting now supported by randomized trial evidence for patients with moderate-to-severe disease and iliac-vein obstruction.
PTS is diagnosed clinically based on persistent symptoms or signs of chronic venous insufficiency ≥3–6 months after DVT, in the absence of recurrent thrombosis.
The Villalta scale is the endorsed diagnostic tool, incorporating 5 symptoms (pain, cramps, heaviness, paresthesia, pruritus) and 6 signs (pretibial edema, skin induration, hyperpigmentation, redness, venous ectasia, pain on calf compression), each scored 0–3. Scores of 5–9 indicate mild PTS, 10–14 moderate, and ≥15 or presence of ulcer indicates severe PTS.
Compression therapy: Elastic compression stockings (ECS), typically knee-high at 20–30 mm Hg, remain the cornerstone of symptomatic management.
Compression level, stocking length, and adherence should be regularly reassessed.
For moderate-to-severe PTS with significant edema, intermittent pneumatic compression devices may be reasonable.
Lifestyle measures: Leg elevation, regular exercise, weight loss, smoking cessation, and avoidance of limb trauma are recommended.
Wound care: For patients with venous ulcers, multilayer compression and oral pentoxifylline are recommended, along with referral to a wound care clinic.
Evidence for pharmacological treatment of established PTS remains limited. Venoactive drugs (rutosides, hidrosmin, defibrotide, micronized purified flavonoid fraction, sulodexide) may provide short-term symptom relief, but long-term effectiveness and safety are uncertain.
Sulodexide has shown some benefit in promoting venous ulcer healing in meta-analysis.
Venoactive drugs may provide short-term relief but are not curative.[2]
Endovascular Therapy
The C-TRACT trial randomized 225 patients with moderate-to-severe PTS and imaging-confirmed iliac-vein obstruction to endovascular therapy (iliac-vein stent placement plus enhanced antithrombotic therapy) plus standard care versus standard care alone:
PTS severity at 6 months was significantly lower with endovascular therapy (mean VCSS 8.1 vs. 10.0.
Venous disease–specific quality of life improved by 14.5 points and SF-36 physical component summary improved by 6.1 points.
Bleeding was more common in the endovascular group (11.6% vs. 3.6%.
Post-stenting antithrombotic therapy in the trial included therapeutic anticoagulation plus aspirin 81 mg daily for at least 6 months.
For severely symptomatic patients with iliac vein or vena cava occlusion refractory to other therapies, considers femoro-femoral or femoro-caval bypass, segmental vein valve transfer, or venous transposition as options.
Optimal anticoagulation after DVT is key for PTS prevention.
Extended anticoagulation beyond 3 months is generally not recommended solely for PTS prevention.
Small studies suggest rivaroxaban may offer better PTS prevention than vitamin K antagonists, and LMWH may have advantages due to anti-inflammatory properties, but no definitive recommendations exist.
Emerging data suggest statins and colchicine may modulate vein wall inflammation and fibrosis, though large trials are lacking.
Early thrombus removal by catheter directed thrombolysis (CDT) can lead to reduction in the incidence of PTS and improve quality of life, however, a study comparing outcomes of catheter directed thrombolysis with anticoagulation versus anti-coagulation alone did not find any significant difference in mortality rates, but evidence of higher adverse events in the CDT group (Bashir R et al).
Use of graded elastic compression stockings for at least 2 years after proximal DVT cuts the rate of postthrombotic syndrome in half.